Caliber Medical Products

Caliber Therapeutics was a clinical-stage medical device and biotechnology company focused on developing innovative drug-eluting technologies for cardiovascular applications. The company's flagship product, the Virtue Sirolimus-Eluting Balloon (SEB), was designed to deliver a proprietary nanoparticle formulation of sirolimus directly to the vessel wall to prevent restenosis without the need for a permanent stent. This approach aimed to address the limitations of drug-eluting stents, particularly in complex lesions and small vessels. Caliber Therapeutics was acquired by Cook Medical in 2013, which integrated the Virtue SEB technology into its global vascular intervention portfolio. The company's work represented a significant advancement in the field of drug-device combination products for interventional cardiology.